SEC Form 4 · accession 0000908662-18-000170

XERIS PHARMACEUTICALS INC · XERS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).

Reporting owners

10% Owner

10% Owner

10% Owner

Period of report

Jun 25, 2018

Accepted (ET)

Jun 25, 2018 · 7:16 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001346302

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1,F2	Jun 25, 2018	C	930,383	—	A	930,383	D
Common Stock^F3,F2	Jun 25, 2018	C	581,992	—	A	1,512,375	D
Common Stock^F4,F2	Jun 25, 2018	C	447,686	—	A	1,960,061	D
Common Stock^F4	Jun 25, 2018	P	150,000	$15.00	A	2,110,061	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Series A Preferred Stock^F1,F2	—	Jun 25, 2018	C	1,657,125	D	—	—	Common Stock	930,383	D
Series B Preferred Stock^F3,F2	—	Jun 25, 2018	C	1,036,599	D	—	—	Common Stock	581,992	D
Series B Preferred Stock^F4,F2	—	Jun 25, 2018	C	797,384	D	—	—	Common Stock	447,686	D

F1The securities are owned by Palmetto Partners, 2014, LP, who is a member of a group with Palmetto Partners, Ltd. and Palmetto Partners 2015, LP.
F2Each share of Preferred Stock automatically converted into Common Stock, for no additional payment or consideration, on a 1.78112-for-1 basis, at the closing of the Issuer's initial public offering on June 25, 2018 and had no expiration date.
F3The securities are owned by Palmetto Partners 2015, LP, who is a member of a group with Palmetto Partners, Ltd. and Palmetto Partners 2014, LP.
F4The securities are owned by Palmetto Partners, Ltd., who is a member of a group with Palmetto Partners 2014, LP and Palmetto Partners 2015, LP.